Mark A Cochran

Bio

Mark served as Managing Director of NeuroVentures from its inception in late 2000 through April 2006. He remains active with several NeuroVentures portfolio companies and continues to serve as an advisor to the firm. Currently, he is Chief Executive Officer and Executive Director of the Blanchette Rockefeller Neurological Research Institute (BRNI) in Morgantown, WV. BRNI is a non-profit research institute dedicated to the study of human memory. Its primary mission is to accelerate neurological discoveries from the lab, including diagnostic tools and treatments, directly to patients who are suffering from neurological diseases such as Alzheimer's. Previously, Dr. Cochran worked with MDS Capital Corporation, a Toronto-based healthcare venture capital group where he was responsible for MDS' San Francisco venture business and several MDS invested companies. His prior experience in the pharmaceutical and biotechnology industry includes Bayer Pharmaceuticals, most recently as vice president of business development, biotechnology, in Berkeley, California. Other positions held during his tenure at Bayer included project director of Recombinant Factor VIII, and head of molecular biology and biochemistry in Wuppertal, Germany. Before joining Bayer, Dr. Cochran co-founded MicroGeneSys, Inc., a Connecticut-based vaccine company. He is listed as the author on 22 scientific papers, 66 abstracts and six patents. Dr. Cochran received his Ph.D. from the Department of Molecular Biology and Immunology at Queen's University in Kingston, Canada. He holds a Masters from the University of Guelph and a B.Sc. from the University of Toronto. Dr. Cochran performed post-doctoral research at the National Institutes of Health in Bethesda, MD.